Skip Ribbon Commands
Skip to main content

News

 

 

Ultimaster Drug Eluting Stent family (Terumo) first stent to receive the mention 1-month DAPT in the reimbursement conditions in Francehttps://www.terumo-europe.com/en-emea/news/ultimaster-drug-eluting-stent-family-first-stent-to-receive-the-mention-1-month-dapt-in-the-reimbursement-conditions-in-frUltimaster Drug Eluting Stent family (Terumo) first stent to receive the mention 1-month DAPT in the reimbursement conditions in FranceLEUVEN, BELGIUM12/7/2022 11:00:00 PM<h4>​Terumo Europe is proud to announce that the HAS (Haute Autorité de Santé) in France has acknowledged in an evidence-based assessment that for the <strong>Ultimaster</strong><sup><strong>TM</strong></sup> and <strong>Ultimaster</strong><sup><strong>TM</strong></sup> <strong>Tansei</strong><sup><strong>TM</strong></sup> stents dual antiplatelet therapy (DAPT) can safely be stopped <strong>after 1 month for High Bleeding Risk patients</strong>. This conclusion is based on the strong and unmatched clinical data generated in the MASTER DAPT study and hence superiority of shortened DAPT regimen can only be attributable and linked to the <strong>Ultimaster</strong><sup><strong>TM</strong></sup> stent.<br><br></h4>
Terumo Pharmaceutical Solutions hosts successful customer collaboration event in South Koreahttps://www.terumo-europe.com/en-emea/news/terumo-pharmaceutical-solutions-hosts-successful-customer-collaboration-event-in-south-koreaTerumo Pharmaceutical Solutions hosts successful customer collaboration event in South KoreaLEUVEN, BELGIUM11/21/2022 11:00:00 PM<h4>​Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation (TSE: 4543) and a leading manufacturer of primary container, injection, infusion therapy devices, and contract development and manufacturing services (CDMO) hosted a successful collaboration customer event in South Korea.<br></h4>
NICE publishes a guidance supporting the use of percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid noduleshttps://www.terumo-europe.com/en-emea/news/nice-publishes-a-guidance-supporting-the-use-of-percutaneous-ultrasound-guided-microwave-ablationNICE publishes a guidance supporting the use of percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodulesLEUVEN, BELGIUM11/15/2022 11:00:00 PM<h4>​Terumo Europe welcomes the <a href="https://www.nice.org.uk/guidance/ipg743" target="_blank">positive guidance released by the National Institute for Health and Care Excellence (NICE)</a> mentioning that microwave ablation can be used provided standard arrangements are in place for clinical governance, consent, and audit. This is positive news as it broadens access to minimally invasive alternatives to surgery available to patients with symptomatic benign thyroid nodules.  <br></h4>
Terumo Pharmaceutical Solutions expands CDMO services outside Japan for global markethttps://www.terumo-europe.com/en-emea/news/terumo-pharmaceutical-solutions-expands-cdmo-services-outside-japan-for-global-marketTerumo Pharmaceutical Solutions expands CDMO services outside Japan for global marketLEUVEN, BELGIUM10/30/2022 11:00:00 PM<h4>​Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation (TSE: 4543) and a leading manufacturer of injection, primary container, and infusion therapy devices, has today announced it will expand its contract development and manufacturing services for parenteral drugs to global customers.<br></h4>
Terumo Pharmaceutical Solutions offers next generation answer for challenging biotech drugshttps://www.terumo-europe.com/en-emea/news/terumo-pharmaceutical-solutions-offers-next-generation-answer-for-challenging-biotech-drugsTerumo Pharmaceutical Solutions offers next generation answer for challenging biotech drugsLEUVEN, BELGIUM10/16/2022 10:00:00 PM<h4><br></h4>